Current phase I/II clinical trials that engineer NK-92 cell lines with CARs to target CD19 (NCT02892695), CD33 (NCT02944162), CD7 (NCT02742727) on acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) cells are ongoing. This evidence concerns the gene CD33 and acute lymphoblastic leukemia.